Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Daiichi's Quizartinib Looks To Join Novartis' Rydapt In AML

Executive Summary

Phase III results for Daiichi Sankyo's FLT3 targeting quizartinib are in, but it's unclear as yet how the data will affect a niche, targeted hematology/oncology market.

You may also be interested in...



More US Positions Go As Daiichi Sankyo Refocuses

Attempts to maximize the current commercial portfolio and prepare for upcoming pipeline launches spell more job losses at the US arm of major Japanese pharma Daiichi Sankyo.

Pipeline Watch: Phase III Starts With Gilteritinib, Lumateperone, Pro 140

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Novartis' Rydapt: Two Indications, Two Prices

Rydapt was approved by the US FDA for the one-third of patients with acute myeloid leukemia who test positive for a FLT3 mutation, which is associated with a poorer prognosis, and for advanced systemic mastocytosis.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC123061

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel